PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

被引：29
|
作者：
Gettinger, Scott [1 ]
Politi, Katerina [1 ]
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 18期
关键词：
IMMUNE ESCAPE; EXPRESSION; ACTIVATION; MUTATIONS;
D O I：
10.1158/1078-0432.CCR-16-1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. (C) 2016 AACR.
引用
收藏
页码：4539 / 4541
页数：3
相关论文
共 50 条
  • [1] Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer
    Doherty, Mark K.
    Korpanty, Grzegorz J.
    Tomasini, Pascale
    Alizadeh, Moein
    Jao, Kevin
    Labbe, Catherine
    Mascaux, Celine M.
    Martin, Petra
    Kamel-Reid, Suzanne
    Tsao, Ming-Sound
    Pintilie, Melania
    Liu, Geoffrey
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Chung, Caroline
    Shepherd, Frances A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 (02) : 195 - 202
  • [2] Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 343 - 356
  • [3] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [4] PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
    Liu, Y.
    Zhu, Y.
    Hu, X.
    Wang, M.
    Zhang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S364 - S364
  • [5] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [6] The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.
    Barron, Carly C.
    Stockley, Tracy
    Law, Jennifer H.
    Shabir, Muqdas
    Fernandes, Roxanne
    Zhang, Tong
    Le, Lisa W.
    Tsao, Ming Sound
    Kamel-Reid, Suzanne
    Pal, Prodipto
    Cabanero, Michael
    Schwock, Joerg
    Ko, Hyangmi
    Liu, Geoffrey
    Bradbury, Penelope Ann
    Sacher, Adrian G.
    Shepherd, Frances A.
    Leighl, Natasha B.
    Perdrizet, Kirstin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: an in silico study
    Alshammari, Saud O.
    Alshammari, Qamar A.
    MOLECULAR DIVERSITY, 2024,
  • [8] Comparison of EGFR and ALK-Driven Lung Adenocarcinoma with Brain Metastases for Prognostic Factors in Chinese Patients
    Wang, F.
    Yang, H.
    Deng, Q.
    Qiu, Y.
    Xu, X.
    Huang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2204 - S2204
  • [9] Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
    Velez, Maria A.
    Burns, Timothy F.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S339 - S342
  • [10] Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).
    Doherty, Mark
    Korpanty, Grzegorz
    Tomasini, Pascale
    Alizadeh, Moein
    Jao, Kevin
    Labbe, Catherine
    Mascaux, Celine
    Martin, Petra
    Kamel-Reid, Suzanne
    Pintilie, Melania
    Liu, Geoffrey
    Bradbury, Penelope Ann
    Feld, Ronald
    Leighl, Natasha B.
    Chung, Caroline
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345